Terminated PHASE2 INTERVENTIONAL 2-arm NCT01349192

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) (STAR-Too)

Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)

Sponsor: Baylor College of Medicine

Conditions Cystic Fibrosis Methicillin-resistant Staphylococcus Aureus

Interventions 2% Chlorhexidine solution wipes Environmental Decontamination Minocycline Mupirocin Rifampin Trimethoprim/Sulfamethoxazole chlorhexidine gluconate oral rinse

Updated 12 times since 2017 Last updated: Apr 5, 2017 Started: Apr 30, 2011 Primary completion: Jan 31, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects

Other terminated trials from Baylor College of Medicine

See all terminations from Baylor College of Medicine

Other Cystic Fibrosis trials with similar outcome

Browse all Cystic Fibrosis trials

Listed as NCT01349192, this PHASE2 trial focuses on Cystic Fibrosis and Methicillin-resistant Staphylococcus Aureus and remains terminated or withdrawn. Sponsored by Baylor College of Medicine, it has been updated 12 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 7 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE2
Aug 2017 — May 2018 [monthly]

Terminated PHASE2
Jul 2017 — Aug 2017 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Feb 2017 — Jul 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor College of Medicine
CF Therapeutics Development Network Coordinating Center
Children's Hospital Medical Center, Cincinnati
Cook Children's Medical Center
Seattle Children's Hospital
St. Louis Children's Hospital
University of Alabama at Birmingham
University of Colorado, Denver
University of Florida
University of Michigan
University of North Carolina, Chapel Hill
University of Texas Southwestern Medical Center
University of Washington
Washington University School of Medicine

Data source: University of North Carolina, Chapel Hill

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Aurora, United States , Birmingham, United States , Chapel Hill, United States , Cincinnati, United States , Dallas, United States , Fort Worth, United States , Gainesville, United States , Houston, United States , Minneapolis, United States and 2 more locations